Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater Associates holds over $56 million worth of shares of GILD, which represents 0.26% of its portfolio.

Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update

A closeup shot of a laboratory technician handling a medical device used for fertility treatments.

On June 26, 2025, Gilead Sciences, Inc. (NASDAQ:GILD) announced the development of its ongoing Phase 2/3 clinical trial that is expected to treat HIV in pediatric patients. The study began in January 2014. It is focused on evaluating the safety, dosage, and effectiveness of cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted Darunavir (DRV/co), and Emtricitabine/Tenofovir Alafenamide (F/TAF) in participants with virologically suppressed HIV-1.

This development highlights the company’s continued commitment to advancing antiretroviral therapies for all age groups. Given the limited number of competitors in the pediatric HIV market, this progress is expected to strengthen Gilead Sciences, Inc.’s (NASDAQ:GILD) market position and boost investors’ confidence.

Gilead Sciences, Inc. (NASDAQ:GILD), a U.S.-based biopharmaceutical company, researches and develops antiviral drugs for patients with HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. GILD is among the list of cheap stocks to buy.

While we acknowledge the potential of GILD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Best Future Food Stocks to Buy According to Analysts and 10 Best Marketing Stocks to Buy Right Now.

Disclosure: None.